{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:09:02Z","timestamp":1794560942600,"version":"4.9.1"},"reference-count":115,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No.2024YFE0213800"],"award-info":[{"award-number":["No.2024YFE0213800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG CRC\/TR 412, Project-ID 535081457, and SFB1382,"],"award-info":[{"award-number":["DFG CRC\/TR 412, Project-ID 535081457, and SFB1382,"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Germany\u2019s Excellence Strategy \u2013 EXC 3118\/1 \u2013 p"],"award-info":[{"award-number":["Germany\u2019s Excellence Strategy \u2013 EXC 3118\/1 \u2013 p"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC82500797"],"award-info":[{"award-number":["NSFC82500797"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,4,27]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide and is tightly linked to cardiometabolic comorbidities. A major clinical focus on MASLD is the detection of hepatic fibrosis, which most strongly predicts liver-related events, hepatocellular carcinoma risk and mortality. While lifestyle modification and sustained weight loss remain foundational, therapeutic innovation has rapidly expanded, shifting the metabolic dysfunction-associated steatohepatitis (MASH) treatment landscape towards targeted pharmacotherapies that address metabolic stress, inflammation and fibrogenesis, particularly for moderate\/advanced fibrosis (\n                    <jats:italic>i.e.<\/jats:italic>\n                    , F2\/F3 fibrosis and cirrhosis). This review summarises the burden and systemic complications of MASLD, highlights endocrine influences that modulate hepatic steatosis and disease severity and emphasises the central role of fibrosis staging and non-invasive risk stratification in clinical decision-making. We then synthesise emerging pharmacotherapies across key mechanistic axes, including incretin-based agents (GLP-1 receptor agonists and dual\/triple agonists), hepatocyte-directed metabolic modulators (thyroid hormone receptor-\u03b2 agonists, fatty acid synthase inhibitors, acetyl-CoA carboxylase and other de novo lipogenesis inhibitors), bile acid pathway therapies (FXR agonists) and pleiotropic metabolic-fibrotic regulators (fibroblast growth factor 21 [FGF21] analogues and peroxisome proliferator-activated receptor [PPAR] agonists). We also discuss combination strategies, candidate agents with potential direct antifibrotic activity and the growing role of genetic risk stratification and hepatocyte-targeted oligonucleotide therapeutics. Finally, we outline current surrogate endpoints used in clinical trials and propose future directions towards stage-specific, mechanism-informed and combination regimens to achieve persistent MASH resolution and meaningful fibrosis regression.\n                  <\/jats:p>","DOI":"10.1136\/bmjgast-2026-002343","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:10:35Z","timestamp":1782994235000},"page":"e002343","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04822181","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02856555","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3643-3006","authenticated-orcid":false,"given":"Fuliang","family":"Li","sequence":"first","affiliation":[{"name":"Department of the First Operating Room, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9766-8385","authenticated-orcid":false,"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastric and Colorectal Surgery, the First Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4923-1948","authenticated-orcid":false,"given":"Dulguun","family":"Juramt","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-3098","authenticated-orcid":false,"given":"Kai","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China"},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-5592","authenticated-orcid":false,"given":"Lanlan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China"},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026070205102247000_13.1.e002343.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"2026070205102247000_13.1.e002343.2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431"},{"key":"2026070205102247000_13.1.e002343.3","doi-asserted-by":"crossref","DOI":"10.4330\/wjc.v17.i6.106147","article-title":"Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis","volume":"17","author":"Bharaj","year":"2025","journal-title":"World J Cardiol"},{"key":"2026070205102247000_13.1.e002343.4","doi-asserted-by":"crossref","unstructured":"Capone F , H\u00e4seli SP , Liu L , et al . HFpEF and MASLD: converging mechanisms and clinical implications. Nat Rev Cardiol 2026. doi:10.1038\/s41569-026-01257-z","DOI":"10.1038\/s41569-026-01257-z"},{"key":"2026070205102247000_13.1.e002343.5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4070\/kcj.2025.0212","article-title":"Cardiovascular implications in metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"56","author":"Suresh","year":"2026","journal-title":"Korean Circ J"},{"key":"2026070205102247000_13.1.e002343.6","doi-asserted-by":"crossref","DOI":"10.4330\/wjc.v18.i1.111954","article-title":"Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review","volume":"18","author":"Brar","year":"2026","journal-title":"World J Cardiol"},{"key":"2026070205102247000_13.1.e002343.7","doi-asserted-by":"crossref","unstructured":"Chowdhary R , Manjeet Kumar G , Ashita Rukmini V , et al . Hepatic outcomes in lean versus non-lean metabolic dysfunction-associated steatotic liver disease: propensity-matched cohort study. Hepatol Res 2026.","DOI":"10.1111\/hepr.70158"},{"key":"2026070205102247000_13.1.e002343.8","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004"},{"key":"2026070205102247000_13.1.e002343.9","doi-asserted-by":"crossref","unstructured":"Zhou X-D , Lazarus JV , Krittanawong C , et al . Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management. Lancet Gastroenterol Hepatol 2026. doi:10.1016\/S2468-1253(25)00323-1","DOI":"10.1016\/S2468-1253(25)00323-1"},{"key":"2026070205102247000_13.1.e002343.10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/dom.70545","article-title":"Providing holistic care for patients with m etabolic dysfunction\u2010associated steatotic liver disease\/metabolic dysfunction\u2010associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions","volume":"28","author":"Chen","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"2026070205102247000_13.1.e002343.11","doi-asserted-by":"crossref","unstructured":"Sattar N , Dalakoti M , Alazawi W , et al . Cardiovascular risk in MASLD: what multiple lines of evidence reveal. J Hepatol 2026. doi:10.1016\/j.jhep.2026.02.015","DOI":"10.1016\/j.jhep.2026.02.015"},{"key":"2026070205102247000_13.1.e002343.12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2025.12.026","article-title":"Is liver steatosis a disease or the emperor\u2019s new clothes?","volume":"84","author":"Krag","year":"2026","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.13","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v17.i2.113149","article-title":"Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: pathophysiology, diagnosis, and emerging therapeutic strategies","volume":"17","author":"Suresh","year":"2026","journal-title":"World J Diabetes"},{"key":"2026070205102247000_13.1.e002343.14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7570\/jomes25017","article-title":"Metabolic dysfunction-associated steatotic liver disease complicated by diabetes: pathophysiology and emerging therapies","volume":"34","author":"Goto","year":"2025","journal-title":"J Obes Metab Syndr"},{"key":"2026070205102247000_13.1.e002343.15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0140-6736(26)00354-5","article-title":"Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study","volume":"407","author":"Graupera","year":"2026","journal-title":"Lancet"},{"key":"2026070205102247000_13.1.e002343.16","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2026070205102247000_13.1.e002343.17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070205102247000_13.1.e002343.18","doi-asserted-by":"crossref","unstructured":"Younossi ZM , de Avila L , Petta S , et al . Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study. Hepatology 2025. doi:10.1097\/HEP.0000000000001617","DOI":"10.1097\/HEP.0000000000001617"},{"key":"2026070205102247000_13.1.e002343.19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"2026070205102247000_13.1.e002343.20","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100218","article-title":"Steatotic liver disease and cancer: from pathogenesis to therapeutic targets","volume":"3","author":"Yang","year":"2025","journal-title":"eGastroenterology"},{"key":"2026070205102247000_13.1.e002343.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2026070205102247000_13.1.e002343.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"2026070205102247000_13.1.e002343.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034"},{"key":"2026070205102247000_13.1.e002343.24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"2026070205102247000_13.1.e002343.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349"},{"key":"2026070205102247000_13.1.e002343.26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"2026070205102247000_13.1.e002343.27","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"2026070205102247000_13.1.e002343.28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026070205102247000_13.1.e002343.29","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100196","article-title":"Key takeaways from the updated multidisciplinary European MASLD guidelines","volume":"3","author":"Horn","year":"2025","journal-title":"eGastroenterology"},{"key":"2026070205102247000_13.1.e002343.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2025-001905","article-title":"Enhanced liver fibrosis test facilitates stratification of people with alcohol use disorder in primary care","volume":"12","author":"Hung","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"2026070205102247000_13.1.e002343.31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026070205102247000_13.1.e002343.32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"key":"2026070205102247000_13.1.e002343.33","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"2026070205102247000_13.1.e002343.34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int"},{"key":"2026070205102247000_13.1.e002343.35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070205102247000_13.1.e002343.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101363","article-title":"Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD","volume":"7","author":"Moolla","year":"2025","journal-title":"JHEP Rep"},{"key":"2026070205102247000_13.1.e002343.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.030"},{"key":"2026070205102247000_13.1.e002343.38","doi-asserted-by":"crossref","unstructured":"Liu H , Lefere S , Guillot A , et al . Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): current knowledge of mechanisms. Hepatology 2025. doi:10.1097\/HEP.0000000000001417","DOI":"10.1097\/HEP.0000000000001417"},{"key":"2026070205102247000_13.1.e002343.39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.006"},{"key":"2026070205102247000_13.1.e002343.40","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cpt.3606","article-title":"Insights into clinical trials for drugs targeting MASLD: progress, challenges, and future directions","volume":"117","author":"Wu","year":"2025","journal-title":"Clin Pharma and Therapeutics"},{"key":"2026070205102247000_13.1.e002343.41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026070205102247000_13.1.e002343.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"2026070205102247000_13.1.e002343.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.033"},{"key":"2026070205102247000_13.1.e002343.44","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad072"},{"key":"2026070205102247000_13.1.e002343.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.004"},{"key":"2026070205102247000_13.1.e002343.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.007"},{"key":"2026070205102247000_13.1.e002343.47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"2026070205102247000_13.1.e002343.48","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334023"},{"key":"2026070205102247000_13.1.e002343.49","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.5.741"},{"key":"2026070205102247000_13.1.e002343.50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"2026070205102247000_13.1.e002343.51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"The Lancet"},{"key":"2026070205102247000_13.1.e002343.52","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026070205102247000_13.1.e002343.53","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7"},{"key":"2026070205102247000_13.1.e002343.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"2026070205102247000_13.1.e002343.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"2026070205102247000_13.1.e002343.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2"},{"key":"2026070205102247000_13.1.e002343.57","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2026","journal-title":"Lancet"},{"key":"2026070205102247000_13.1.e002343.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"2026070205102247000_13.1.e002343.59","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330596"},{"key":"2026070205102247000_13.1.e002343.60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"2026070205102247000_13.1.e002343.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2026070205102247000_13.1.e002343.63","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2024-100074","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Li","year":"2024","journal-title":"egastro"},{"key":"2026070205102247000_13.1.e002343.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.012"},{"key":"2026070205102247000_13.1.e002343.65","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M001602"},{"key":"2026070205102247000_13.1.e002343.66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"2026070205102247000_13.1.e002343.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.014"},{"key":"2026070205102247000_13.1.e002343.68","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070205102247000_13.1.e002343.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.034"},{"key":"2026070205102247000_13.1.e002343.70","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med Res Rev"},{"key":"2026070205102247000_13.1.e002343.71","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00246-2"},{"key":"2026070205102247000_13.1.e002343.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.042"},{"key":"2026070205102247000_13.1.e002343.73","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.027"},{"key":"2026070205102247000_13.1.e002343.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.04.042"},{"key":"2026070205102247000_13.1.e002343.75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav9701","article-title":"Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis","volume":"11","author":"Amin","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026070205102247000_13.1.e002343.76","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2\u2013F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026070205102247000_13.1.e002343.77","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"The Lancet"},{"key":"2026070205102247000_13.1.e002343.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"2026070205102247000_13.1.e002343.79","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"2026070205102247000_13.1.e002343.80","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070205102247000_13.1.e002343.81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"The Lancet"},{"key":"2026070205102247000_13.1.e002343.82","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070205102247000_13.1.e002343.83","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMc2311873","article-title":"Randomized trial of pegozafermin in NASH","volume":"389","author":"Patoulias","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070205102247000_13.1.e002343.84","doi-asserted-by":"publisher","DOI":"10.1016\/J.CMET.2021.12.024"},{"key":"2026070205102247000_13.1.e002343.85","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100319","article-title":"Metabolic dysfunction and alcohol-associated liver disease (MetALD)","volume":"3","author":"Gao","year":"2025","journal-title":"eGastroenterology"},{"key":"2026070205102247000_13.1.e002343.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.039"},{"key":"2026070205102247000_13.1.e002343.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.025"},{"key":"2026070205102247000_13.1.e002343.88","doi-asserted-by":"crossref","first-page":"102174","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026070205102247000_13.1.e002343.89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205"},{"key":"2026070205102247000_13.1.e002343.90","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/HEP.0000000000001475","article-title":"Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: a phase II, randomized, double-blind, placebo-controlled study","volume":"83","author":"Sun","year":"2026","journal-title":"Hepatology"},{"key":"2026070205102247000_13.1.e002343.91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101421","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Rep"},{"key":"2026070205102247000_13.1.e002343.92","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/cts.13581","article-title":"Pharmacokinetics, safety, and tolerability of BMS\u2010986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment","volume":"16","author":"Qosa","year":"2023","journal-title":"Clinical Translational Sci"},{"key":"2026070205102247000_13.1.e002343.93","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial.","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026070205102247000_13.1.e002343.94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adx0368","article-title":"Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction\u2013associated steatohepatitis","volume":"18","author":"Yashaswini","year":"2026","journal-title":"Sci Transl Med"},{"key":"2026070205102247000_13.1.e002343.95","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00974-5"},{"key":"2026070205102247000_13.1.e002343.96","doi-asserted-by":"crossref","unstructured":"Dong J , Hillman S , Dixon S , et al . Hormone replacement therapy for menopausal symptoms and the risk of cardiometabolic disease: current evidence and future directions. BJOG 2026. doi:10.1111\/1471-0528.70214","DOI":"10.1111\/1471-0528.70214"},{"key":"2026070205102247000_13.1.e002343.97","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70616","article-title":"Hormone replacement therapy to tackle MASLD progression in peri-menopausal women: window of opportunity or call for precision?","volume":"46","author":"Chen","year":"2026","journal-title":"Liver Int"},{"key":"2026070205102247000_13.1.e002343.98","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70562","article-title":"Effect of hormone replacement therapy on liver and cardiometabolic outcomes in peri-menopausal MASLD","volume":"46","author":"Henney","year":"2026","journal-title":"Liver Int"},{"key":"2026070205102247000_13.1.e002343.99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00634-7"},{"key":"2026070205102247000_13.1.e002343.100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03480-y"},{"key":"2026070205102247000_13.1.e002343.101","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"2026070205102247000_13.1.e002343.102","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000439"},{"key":"2026070205102247000_13.1.e002343.103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.104","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2025.04.035","article-title":"High inherited risk predicts age-associated increases in fibrosis in patients with MASLD","volume":"83","author":"D\u00edaz","year":"2025","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.105","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab"},{"key":"2026070205102247000_13.1.e002343.106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.107","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","article-title":"Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis","volume":"83","author":"Sanyal","year":"2025","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.016"},{"key":"2026070205102247000_13.1.e002343.109","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"key":"2026070205102247000_13.1.e002343.110","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","article-title":"Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants","volume":"163","author":"Ajmera","year":"2022","journal-title":"Gastroenterology"},{"key":"2026070205102247000_13.1.e002343.111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.034"},{"key":"2026070205102247000_13.1.e002343.112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2026070205102247000_13.1.e002343.113","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"2026070205102247000_13.1.e002343.114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"2026070205102247000_13.1.e002343.115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:10:58Z","timestamp":1782994258000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjgast-2026-002343"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002343","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}